Technical Articles

Ovarian cancer, as the deadliest gynecological malignancy, has a five-year survival rate of less than 50%, primarily attributed to late-stage diagnosis, strong heterogeneity, and low response rates to immunotherapy. Despite breakthroughs with immune checkpoint inhibitors (ICIs) in various solid tumors, the objective response rate (ORR) in ovarian cancer remains below 15%.